_20240812185757_original_image_50.webp){kind=spacer}
Stryker, a leader in medical technologies, has announced the launch of InSpace, a biodegradable subacromial balloon implant designed for the arthroscopic treatment of massive irreparable rotator cuff tears (MIRCTs) in India.
MIRCTs are a prevalent cause of shoulder dysfunction, and InSpace offers a novel, minimally invasive option for surgeons to address these challenging cases. In a press statement on Monday, the company informed that the InSpace balloon implant is unique in its approach, as it restores the subacromial space without the need for sutures or fixation devices. This innovation has been shown to enhance shoulder motion and function significantly.
Aman Rishi, Vice President and General Manager for Stryker in India, remarked, “InSpace represents a significant advancement in shoulder arthroscopy. This first-of-its-kind technology provides surgeons with a new, minimally invasive option to address MIRCTs, potentially leading to earlier functional recovery and pain relief for patients. We are committed to pushing the boundaries of shoulder care and improving patient outcomes.”
With a successful clinical history spanning over 14 years, InSpace has been featured in 35 peer-reviewed articles and has seen 41,000 implants worldwide. The implant offers several clinically proven advantages:
Less invasive: Provides a streamlined surgical solution compared to traditional methods that require fixation devices or grafts.
Early improvement: Shows clinically meaningful gains in shoulder motion and function post-surgery.
Enhanced range of motion: On average, patients experience increased motion compared to those undergoing partial repairs.
Comparable safety and effectiveness: Demonstrates similar long-term safety and efficacy to partial repairs, with over 87 per cent clinical success at two years for patients aged 65 and older.
